Nielsen, Peter Brønnum
Larsen, Torben Bjerregaard
Skjøth, Flemming
Overvad, Thure Filskov
Lip, Gregory Y. H.
Article History
Received: 14 March 2016
Accepted: 18 May 2016
First Online: 6 June 2016
Competing interests
: PBN: Speaker for Boehringer Ingelheim. GYHL: Guideline membership/reviewing for various guidelines and position statements from ESC, EHRA, NICE etc. Steering Committees/trials: Includes steering committees for various Phase II and III studies, Health Economics & Outcomes Research, etc. Investigator in various clinical trials in cardiovascular disease, including those on antithrombotic therapies in atrial fibrillation, acute coronary syndrome, lipids, etc. Consultant for Bayer/Jensen J&J, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. TBL: Investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim and have been on the speaker bureaus for Bayer, BMS/Pfizer, Roche Diagnostics, Boehringer Ingelheim and Takeda Pharma.